Neurogastrx Shows It Can Offset GLP-1 Side Effects
Firm Thinks Payers Will Cover An Add-On To Improve Compliance
A Phase II study shows that D2 receptor antagonist NG101 can significantly reduce nausea and vomiting in patients taking Novo Nordisk’s semaglutide for obesity.
